🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCrypto & PrivacyCryptocurrency payment adoption by compounding pharmacies — my results so far

Cryptocurrency payment adoption by compounding pharmacies — my results so far

wanda_boise Mon, May 11, 2026 at 11:53 PM 27 replies 566 viewsPage 1 of 6
wanda_boise
Member
412
1,890
Aug 2024
Boise, ID
May 11, 2026 at 11:53 PM#1

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

What I am trying to establish is why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission.

Happy to be told the question itself is wrong.

31 1DanielChem_CHI, marco_milano, pam_columbus and 28 others
Reply Quote Save Share Report
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
May 12, 2026 at 12:28 AM#2

Answering the narrow version, because the broad one does not have a single answer. Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists. For 503B the shortage clause was the only route to these molecules, so that route shut completely. A 503A pharmacy can still argue a doorway via "component of an approved drug" — but only for the substance in the form present in the approved product, which is exactly where the base-versus-salt argument lives, and it does nothing about the copy restriction, which came back into force on resolution.

I would rather be corrected than agreed with, if it comes to it.

30 0VendorMark, COA_Karl, MikeFit_NJ and 27 others
Reply Quote Save Share Report
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
May 12, 2026 at 1:03 AM#3
Dr.GastroMayo said:
Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.

Dr.GastroMayo has the substance of this right. The condition it depends on is worth stating. Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces a significant clinical difference for that patient. A grid of fixed doses offered to everybody is not that, whatever the intake form says.

29 24patPC_UT, Dr.DermMIA, fiona_VT and 26 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
LindaRN_retired
Member
189
890
Dec 2024
Sarasota, FL
May 12, 2026 at 1:38 AM#4
wanda_boise said:
My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Same position here, arrived at the long way round. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

28 23LondonLisa, mike_nyc, VendorMark and 25 others
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
May 12, 2026 at 4:55 AM#5

Clinical perspective, offered as context rather than as advice.

Price comparison for compounded supply across sources I've used:

SourceMonthly CostTypePurity Verified
Brand (Ozempic)$920FDA-approvedN/A (pharma)
503B Compounding$150cGMP compoundedYes (in-house)
503A Compounding$110Patient-specificVaries
Research peptide$60Not for human useOften Janoshik

I use the 503B option — best balance of quality, cost, and legality. The brand price is insane but insurance can help if you qualify.

27 22FranDenver, Dr.BariatricHTX, LindaRN_retired and 24 others
Reply Quote Save Share Report
1236

Similar Threads

Monero vs Lightning Network for pharmacy payments — privacy comparison18 replies
Bitcoin payment guide for peptide purchases9 replies
Cryptocurrency payment adoption by compounding pharmacies — 20267 replies
Privacy coins and HIPAA — does crypto payment enhance medical privacy?8 replies
Escrow services for international peptide orders6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register